ツチヤ　ケン   Tsuchiya Ken   土谷　健    所属   医学部 医学科（東京女子医科大学病院）    職種   特任教授
論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	Eicosapentaenoic Acid (EPA) Decreases the All-Cause Mortality in Hemodialysis Patients
掲載誌名	正式名：Internal medicine (Tokyo, Japan) 略　 称：Intern Med ISSNコード：1349-7235(Electronic)0918-2918(Linking)
掲載区分	国外
巻・号・頁	54(24),pp.3133-7
著者・共著者	Inoue Tomoko, Okano Kazuhiro, Tsuruta Yuki, Tsuruta Yukio, Tsuchiya Ken, Akiba Takashi, Nitta Kosaku
発行年月	2015/12/15
概要	Objective Atherosclerosis, which causes cardiovascular disease, is a major cause of death in hemodialysis (HD) patients. Eicosapentaenoic acid (EPA), an anti-hyperlipidemic agent, is known to have antioxidative or anti-inflammatory effects, resulting in improvements in atherosclerosis. In the present study, we examined whether EPA improves the all-cause mortality in patients receiving regular HD therapy. Methods We enrolled 176 patients treated with maintenance HD therapy and performed a longitudinal observational cohort study for three years. We divided the patients into two groups based on whether or not the received EPA treatment [EPA(+) and EPA(-), respectively]. The primary end-point was all-cause death. We also matched the two groups using propensity score matching and examined the effect of EPA. Results Before matching, the all-cause mortality rates were 24.0% in the EPA(+) and 11.8% in the EPA(-) groups, which were significantly different (p=0.044). After propensity score matching, the EPA(+) group still showed a significantly better prognosis than the EPA(-) group (p=0.038). A multivariate analysis showed that EPA treatment significantly reduced the risk of all-cause mortality both before and after propensity score matching. Conclusion EPA treatment is independently associated with lower mortality in HD patients.
DOI	10.2169/internalmedicine.54.4931
PMID	26666599